Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 patients

Early diagnosis by testing in an early stage of disease and early intervention by
effective drugs might alter the course of the disease especially in the population most
at risk for severe course of disease.
In a population-based approach, altering the course of disease in this population
most at risk can prevent hospital admissions and intensive care thus alleviating the
pressure on the healthcare system.
In the proposed study patients will be randomized in a 2:1 ratio to either hydroxychloroquine
or placebo.
Patients and investigators, as well as treating physicians will be blinded to treatmentallocation.